Seres Therapeutics Inc. (NASDAQ:MCRB) shares traded down 2.9% during mid-day trading on Thursday . The stock traded as low as $10.55 and last traded at $10.64, with a volume of 396,560 shares. The stock had previously closed at $10.96.

Several research analysts have recently issued reports on the stock. FBR & Co reiterated a “buy” rating on shares of Seres Therapeutics in a report on Friday, July 8th. Leerink Swann reiterated an “outperform” rating and set a $12.00 price target (down from $43.00) on shares of Seres Therapeutics in a report on Monday, August 1st. Cowen and Company assumed coverage on shares of Seres Therapeutics in a report on Monday, June 6th. They set an “outperform” rating for the company. Bank of America Corp. downgraded shares of Seres Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 1st. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Seres Therapeutics in a report on Sunday, May 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $31.57.

The firm’s market cap is $438.18 million. The firm has a 50 day moving average of $19.89 and a 200 day moving average of $25.82.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.24. The business had revenue of $3 million for the quarter, compared to analysts’ expectations of $4.20 million. Seres Therapeutics’s revenue for the quarter was up NaN% on a year-over-year basis. During the same period last year, the firm posted ($1.45) earnings per share. Equities analysts forecast that Seres Therapeutics Inc. will post ($2.32) EPS for the current year.

In other Seres Therapeutics news, EVP John G. Aunins sold 9,390 shares of the firm’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $27.23, for a total value of $255,689.70. Following the completion of the transaction, the executive vice president now directly owns 32,655 shares of the company’s stock, valued at approximately $889,195.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP David N. Cook sold 16,000 shares of the firm’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $29.43, for a total transaction of $470,880.00. Following the completion of the transaction, the executive vice president now directly owns 144,673 shares of the company’s stock, valued at $4,257,726.39. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Seres Therapeutics stock. Jennison Associates LLC increased its stake in shares of Seres Therapeutics Inc. (NASDAQ:MCRB) by 1.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 398,959 shares of the company’s stock after buying an additional 7,259 shares during the period. Jennison Associates LLC owned 1.02% of Seres Therapeutics worth $13,999,000 as of its most recent filing with the SEC.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.